Abeona Therapeutics (NASDAQ: ABEO) and Ohr Pharmaceuticals (NASDAQ:OHRP) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, analyst recommendations, profitability, institutional ownership and risk.

Earnings & Valuation

This table compares Abeona Therapeutics and Ohr Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Abeona Therapeutics $890,000.00 804.20 -$21.87 million ($0.65) -23.54
Ohr Pharmaceuticals N/A N/A -$25.76 million ($0.70) -2.01

Abeona Therapeutics has higher revenue and earnings than Ohr Pharmaceuticals. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Ohr Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Abeona Therapeutics and Ohr Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abeona Therapeutics 0 0 9 0 3.00
Ohr Pharmaceuticals 0 0 2 0 3.00

Abeona Therapeutics currently has a consensus target price of $27.00, indicating a potential upside of 76.47%. Ohr Pharmaceuticals has a consensus target price of $8.50, indicating a potential upside of 502.84%. Given Ohr Pharmaceuticals’ higher probable upside, analysts clearly believe Ohr Pharmaceuticals is more favorable than Abeona Therapeutics.

Risk & Volatility

Abeona Therapeutics has a beta of 2.36, meaning that its stock price is 136% more volatile than the S&P 500. Comparatively, Ohr Pharmaceuticals has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.


This table compares Abeona Therapeutics and Ohr Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Abeona Therapeutics -2,946.58% -27.69% -25.32%
Ohr Pharmaceuticals N/A -103.56% -85.09%

Insider & Institutional Ownership

42.0% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 8.4% of Ohr Pharmaceuticals shares are owned by institutional investors. 6.8% of Abeona Therapeutics shares are owned by insiders. Comparatively, 17.4% of Ohr Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


Abeona Therapeutics beats Ohr Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

About Abeona Therapeutics

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

About Ohr Pharmaceuticals

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.